Transaction DateRecipientSharesTypePriceValue
20th January 2021Oliver Christian Bennett4,399Open or private sale$4.49$19,752.39
13th January 2021Hove Caroline F. Van1,973Open or private sale$4.71$9,300.52
12th January 2021Keith J Sullivan125,000Grant/award etc.$0.00
7th January 2021Oliver Christian Bennett3,665Payment by withholding$4.26$15,612.90
11th November 2020Kevin C Oboyle16,306Disposition due to a tender of shares in a change of control transaction$30.75$501,409.50
8th November 2020Hove Caroline F. Van100,000Grant/award etc.$0.00
12th October 2020Paul Sean Little50,000Grant/award etc.$0.00
12th October 2020Oliver Christian Bennett50,000Grant/award etc.$0.00
3rd September 2020Paul Sean Little5,763Payment by withholding$3.54$20,401.02
14th July 2020Keith J Sullivan500,000Grant/award etc.$0.00
Sientra
Sientra logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Sientra, Inc. engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra,. AlloX2, Dermaspan, Softspan and BIOCORNEUM.


Ticker: SIEN
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1551693
Employees: 259
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $72 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $145 M (-8%)
Property, Plant and Equipment, Net: $13 M (0%)
Other Assets, Noncurrent: $9 M (6%)
Assets: $185 M (0%)
Accounts Payable, Current: $4 M (-59%)
Accrued Liabilities, Current: $23 M (0%)
Liabilities, Current: $51 M (-28%)
Long-term Debt, Excluding Current Maturities: $63 M (65%)
Liabilities: $163 M (33%)
Common Stock, Value, Issued: $503 Th (1%)
Common Stock, Shares, Issued: $50 M (1%)
Additional Paid in Capital, Common Stock: $554 M (0%)
Retained Earnings (Accumulated Deficit): $532 M (13%)
Stockholders' Equity (Parent): $22 M (0%)
Liabilities and Equity: $185 M (-9%)
Revenue: $12 M (0%)
Cost of Revenue: $6 M (-55%)
Gross Margin: $7 M (-59%)
Research and Development: $3 M (-51%)
Sales and Marketing: $8 M (-67%)
General and Administrative Expenses: $8 M (-53%)
Restructuring Charges: $496 Th (-77%)
Operating Income/Loss: $12 M (0%)
Other Income, net: $22 M (-6%)